Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Eunjin Lee 1 and Ji Eun Oh 1,2, *
1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea, 2BioMedical Research Center, KAIST, Daejeon 34141, Korea
Received April 4, 2021; Revised April 22, 2021; Accepted April 23, 0021.; Published online June 1, 2021.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARSCoV-2 variants, and highlight gaps in the current knowledge.
Keywords: COVID-19, humoral immunity, neutralizing antibody, SARS-CoV-2, SARS-CoV-2 variants

Current Issue

31 May 2021 Volume 44,
Number 5, pp. 279~373
COVER PICTURE The immune system is an organic network of biological processes that protects the host from disease. Immune cells detect a wide variety of pathogens and responds with sophisticated mechanisms to maintain homeostasis. (Kim et al., pp. 301-309).

This Article

Cited By Articles
  • CrossRef (0)

Social Network Service

Indexed in

  • Science Central
  • CrossMark